Maven Securities’s Immunome IMNM Stock Holding History

Maven Securities’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-75,000	Closed	-$1.61M	–	481
2025 Q4	$1.61M	Buy	+75,000	New	+$1.32M	0.04%	332

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Maven Securities's IMNM Position: Q1 2026 in Review

Maven Securities sold out of Immunome (IMNM) in Q1 2026, closing a stake of 75,000 shares — an estimated $1.61M sold.

Maven Securities first reported a position in IMNM in Q4 2025 and held it in 1 quarter. The position peaked at $1.61M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

Maven Securities reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
Maven Securities sold 75,000 Immunome shares in Q1 2026, an estimated $1.61M.
Maven Securities first reported a position in Immunome in Q4 2025 and held it in 1 quarter.
Maven Securities's Immunome position peaked at $1.61M in Q4 2025.
200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.